Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$316.00K$316.00Kderived+54.1% vs Q4 2014 Net Income-$1.89M-$1.89MderivedN/M vs Q4 2014 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,896,000N/M Operating Cash Flowderived-$1,207,000N/M Free Cash Flowderived-$1,205,000N/M Margins · derivedOperating margin-600.0%−39.0 pt vs Q4 2014
Net margin-596.5%−39.9 pt vs Q4 2014
ended Jun 30, 2015 · filed Oct 13, 2015 · 105 d after period end